Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., liver). Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure on the individual.
1. A liposome-based nanocarrier comprising:
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl) (succinyl-DPPE);
an organic polymer comprising polyethylene glycol (PEG), wherein the concentration of PEG is from about 0.5 wt. % to about 10 wt. % of the liposome-based nanocarrier; and
an associated drug selected from the group consisting of a free radical scavenger or a radioprotectant,
wherein the liposome-based nanocarrier has a surface having a negative charge due to succinyl-DPPE, and
wherein the liposome-based nanocarrier selectively targets bone marrow or lymph nodes.
2. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier comprises a member selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl) (succinyl PE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE).
3. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier comprises a lipid labeled with an isotope and chelator.
4. The liposome-based nanocarrier of claim 3 , wherein the isotope comprises a member selected from the group consisting of 64 Cu, 66 Ga, 86 Y, 111 In, 67 Ga, 68 Ga, 124/131 I, and 177 Lu.
5. The liposome-based nanocarrier of claim 3 , wherein the chelator comprises a member selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-trisacetic acid (NOTA).
6. The liposome-based nanocarrier of claim 3 , wherein the chelator comprises a member selected from the group consisting of DOTA-Bn-DSPE and NOTA-Bn-DSPE.
7. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol) (mPEG-DSPE).
8. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier is at least 3 mole % lipid.
9. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier has an average diameter in a range from 30 nm to 300 nm.
10. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier is from one or more of (i), (ii), and (iii), as follows:
(i) from 3 to 20 wt. % succinyl DPPE;
(ii) from 0.5 to 2 wt. % PEG; and
(iii) from 5 to 9 wt. % PEG.
11. The liposome-based nanocarrier of claim 1 , wherein the negative charge of the surface of the liposome-based nanocarrier is from −15 mV to −25 mV.
12. A method for imaging a subject the method comprising:
administering to the subject a liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier comprises a lipid labeled with an isotope and a chelator.
13. The method of claim 12 , further comprising obtaining and displaying a positron emission tomography (PET) and/or Positron emission tomography—computed tomography (PET/CT) image of at least one tissue of the subject comprising the liposome-based nanocarrier.
14. The method of claim 12 , further comprising quantitatively measuring a distribution of the liposome-based nanocarrier in at least one tissue of the subject.
15. The method of claim 14 , the method comprising quantitatively measuring the distribution of the liposome-based nanocarrier in an organ of the reticuloendothelial system.
16. The method of claim 15 , wherein the organ comprises a member selected from the group consisting of liver, spleen, and bone marrow.
17. The method of claim 15 , comprising determining a concentration and/or total amount of delivered radiolabeled drug in the tissue based on a positron emission tomography (PET) or Positron Emission Tomography—Computed Tomography (PET/CT) image of the tissue.
18. The method of claim 14 , the method comprising
quantitatively measuring the distribution of the liposome-based nanocarrier in one or more lymph nodes.
19. The method of claim 12 , wherein the administered liposome-based nanocarrier demonstrates selective targeting of bone marrow of the subject such that concentration of the liposome-based nanocarrier in bone marrow is at least 3 fold greater than the concentration of the liposome-based nanocarrier in any of the tumor tissue at a given time following administration of the liposome-based nanocarrier, wherein the given time is at least 1 hour following administration.
20. The method of claim 12 , further comprising capturing and displaying a sequence of PET images in real time.
21. A method of treating a subject, the method comprising administering the liposome-based nanocarrier of claim 1 to the subject suffering from or susceptible to a disease and/or condition.
22. The method of claim 21 , wherein the disease and/or condition comprises a member selected from the group consisting of bone marrow suppression (BMS), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), sepsis, graft-versus-host-disease (GVHD), bone metastasis, and osteoporosis.
23. The method of claim 21 , wherein the disease and/or condition comprises exposure to radiation.
24. The method of claim 22 , the method further comprising after administering the liposome-based nanocarrier, administering a chemotherapeutic and/or radiation therapy.
25. The method of claim 21 , wherein the administered liposome-based nanocarrier demonstrates selective targeting of bone marrow of the subject such that the concentration of the liposome-based nanocarrier in bone marrow is at least 3 fold greater than the concentration of the liposome-based nanocarrier in any of the tumor tissue at a given time following administration of the liposome-based nanocarrier,
wherein the given time is at least 1 hour, following administration.
26. A method of monitoring a patient, the method comprising
administering the liposome-based nanocarrier of claim 1 to a patient suffering from or susceptible to a disease and/or condition; and
investigating a quantity of drug delivered to at least one tissue of the patient.
27. A method of imaging an organ of the reticuloendothelial system in a subject, the method comprising:
detecting radiation from the liposome-based nanocarrier of claim 1 , the subject having been administered the liposome-based nanocarrier.
28. The method of claim 27 , wherein the radiation is detected via an external PET imaging system.
29. The method of claim 27 , wherein the organ comprises a member selected from the group consisting of active bone marrow, liver, and spleen.
30. The method of claim 27 , the method further comprising displaying an image corresponding to the detected radiation, the image visually distinguishing active bone marrow from other tissue and, optionally, quantifying the concentration of drug and/or liposome based nanocarrier.
31. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier has an average diameter in a range from 50 nm to 200 nm.
32. The liposome-based nanocarrier of claim 1 , wherein the liposome-based nanocarrier comprises a radiolabel.
33. The liposome-based nanocarrier of claim 1 , wherein the nanocarrier is from 0.5 wt. % to 2 wt. % PEG and wherein the liposome-based nanocarrier selectively targets bone marrow.
34. The liposome-based nanocarrier of claim 1 , wherein the nanocarrier is from 5 wt. % to 9 wt. % PEG and wherein the liposome-based nanocarrier selectively targets lymph nodes.